The rising costs of dementia medications, particularly Lecanemab priced at $26,500 annually, pose significant challenges for Medicare, which may face pressure to restrict coverage or raise premiums.
The rising costs of dementia medications, particularly Lecanemab priced at $26,500 annually, pose significant challenges for Medicare, which may face pressure to restrict coverage or raise premiums.
The rising costs of dementia medications, particularly Lecanemab priced at $26,500 annually, pose significant challenges for Medicare, which may face pressure to restrict coverage or raise premiums.
Leave a Comment